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Current guidelines recommend transarterial chemoembolization (TACE) as the standard treatment of Barcelona-Clinic
Liver Cancer (BCLC)-B patients. However, the long-term survival outcomes of patients managed with this technique do
not appear fully satisfactory; in addition, intermediate-stage hepatocellular carcinoma (HCC) includes a heterogeneous
population of patients with varying tumour burdens, liver function and disease aetiology. Therefore, not all patients with
intermediate-stage HCC may derive similar beneﬁt from TACE, and some patients may beneﬁt from other treatment
options, which are currently approved or being explored. These include different TACE modalities, such as selective
TACE or drug-eluting beads TACE and radioembolization. The introduction of sorafenib in the therapeutic
armamentarium for HCC has provided a new therapeutic option for the treatment of BCLC-B patients who are
unsuitable to TACE or in whom TACE resulted in unacceptable toxicity. In addition, clinical trials aimed at investigating
the potential role of this molecule in the treatment of patients with intermediate-stage HCC within combination
therapeutic regimens are ongoing. This narrative review will present and discuss the most recent evidence on the
locoregional or medical treatment with sorafenib in patients with intermediate-stage HCC.
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The recent guidelines issued by the European Association for
the Study of Liver (EASL) endorse the Barcelona-Clinic Liver
Cancer (BCLC) classiﬁcation for the staging of hepatocellular
carcinoma (HCC) [1,2]. This classiﬁcation divides HCC
patients into ﬁve stages (0, A, B, C and D) according to
different prognostic variables and allocates therapies according
to treatment-related status [1].
About 20% of HCC patients are classiﬁed as affected by
BCLC-B, or intermediate-stage HCC, and present a 2-year
survival of ∼50% [1]. The management of these patients, like
that of other HCC subjects, should be based on the
multidisciplinary interaction among different specialists [1].
Current guidelines recommend transarterial
chemoembolization (TACE) as the standard treatment of
BCLC-B patients [1,3,4]. However, despite several recent
advances and technical reﬁnements, the long-term survival
outcomes of patients managed with this technique do not
appear fully satisfactory [3]; in addition, intermediate-stage
HCC includes a heterogeneous population of patients with
varying tumour burdens, liver function and disease aetiology
[3–5 ]. As reported by Piscaglia and Bolondi [5], both a patient
with still well-preserved liver function (Child-Pugh A5 due to
albumin 4.8 g/dl, total bilirubin 0.9 mg/dl, INR 0.99) and only
two nodules <3 cm and a patient with persistent ascites and
jaundice (Child-Pugh B) with multifocal large tumours will be
classiﬁed as affected by intermediate-stage HCC.
Therefore, not all patients with intermediate-stage HCC will
derive similar beneﬁt from TACE, and some patients may
beneﬁt from other treatment options, which are currently
approved or being explored (Figure 1) [3–6]. These include
different TACE modalities, such as selective TACE or drug-
eluting beads (DB)-TACE, and radioembolization or
combination approaches [3–6]. For instance, the combination
of TACE and radiofrequency ablation gave promising results in
a recent study [6].
The introduction of sorafenib in the therapeutic
armamentarium for HCC has provided a new therapeutic
option for the treatment of BCLC-B patients who are
unsuitable to TACE or in whom TACE resulted in
unacceptable toxicity. In addition, clinical trials aimed at
investigating the potential role of this molecule in the
treatment of patients with intermediate-stage HCC within
combination therapeutic regimens are ongoing.
This review will present and discuss the most recent
evidence on the locoregional or medical treatment with
sorafenib in patients with intermediate-stage HCC. Surgical
procedures, including resection or transplantation, can be
considered in selected patients, as reviewed in Zhang et al. [7].
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Resection may be a valid option in selected patients [7]. More
in detail, radical resection can be considered in: (i) patients
with single HCC and large tumour nodule, swelling outward,
clear border or pseudocapsule and <30% hepatic tissue
destroyed or >50% compensatory hepatic hypertrophy and (ii)
patients with multiple HCC with ≤3 nodules localized in one
lobe or segment of the liver [7]. Other patients may be eligible
for palliative resection (see Zhang et al. [7] for a deeper
discussion on indication for palliative resection). Due to the
shortage of available organs, it is currently recommended that
only those HCC patients with an estimated high probability of
post-transplant survival beneﬁt may be selected for liver
transplantation. The Milan criteria (1 lesion ≤5 cm or 2–3
lesions ≤3 cm), proposed in 1996, still represent the basis for
the selection of the best candidates for liver transplant [7–
10]. However, the adoption of expanded and/or down-staging
criteria for liver transplant has been proposed and is currently
under clinical investigation [7–10]. For instance, a study by
Mazzaferro—the leading investigator of the team who
identiﬁed the same Milan criteria —conducted on 1556
patients has suggested that more HCC patients could be
eligible for transplantation if the Milan criteria were replaced
by a more precise estimation of survival based on individual
tumour characteristics and up-to-seven criteria [8].
These ﬁndings are conﬁrmed by a study on more than 6000
patients included in the US Scientiﬁc Registry of Transplant
Recipients database: this analysis shows that the Milan criteria
are too restrictive, and patients with larger total tumour
volume can enjoy satisfactory post-transplant survivals [11].
Moreover, a composite patient selection score combining total
tumour volume and alpha fetoprotein can be considered the
most effective of all tested staging criteria for the prediction of
the survival of transplanted patients [11].
locoregional options for the
intermediate patient
The most widely used locoregional therapies for the treatment
of intermediate-stage HCC are TACE, selective TACE, DB-
TACE and radioembolization [3,4,7,12–14]. These
interventions are image-guided and therefore a careful
imaging, also before and after treatment, represents an essential
prerequisite for their success [12,13]. A detailed description of
the imaging modalities for locoregional treatments is beyond
the scopes of this review.
transarterial chemoembolization
TACE is considered as the standard treatment of patients with
compensated liver function (Child B up to 8 points), with large
single nodule or multifocal HCC (<5 cm) not occluding the
portal venous vessels and without extrahepatic spread
[3,14,15]. Survival beneﬁts determined by TACE were reported
in two randomized, controlled trials (RCTs): Llovet et al. [16]
showed a signiﬁcant survival advantage in favour of TACE over
transarterial embolization [hazard ratio (HR) for death: 0.47;
95% conﬁdence interval (CI), 0.25–0.91; P = 0.025], and Lo
et al. [17] showed a 50% reduction in the relative risk of death
with TACE versus symptomatic treatment (95% CI, 0.31–0.81;
P = 0.005). In addition, the efﬁcacy of TACE has been
evaluated in other RCTs, and two of these did not show a
prolonged survival time with respect to controls [18,19].
Despite this, the results of a meta-analysis published in 2003
indicated that treatment with transarterial embolization/TACE
is associated with a signiﬁcantly higher 2-year survival rate
than in the control group (odds ratio, 0.53; 95% CI, 0.32–0.89;
P = 0.017) [20]. These ﬁndings are in agreement with those
reported in another meta-analysis of 18 RCTs, which shows
that TACE improves the overall survival (OS) at 2 years
compared with non-active treatment; however, the magnitude
of this beneﬁt is relatively small [21].
TACE-associated adverse events (AEs), although usually
transient and manageable, occur in a signiﬁcant proportion
(35–100%) of patients: they include post-embolization
syndrome (comprising fever, abdominal pain and a moderate
degree of ileus), relevant liver function deterioration, ascites
and gastrointestinal bleeding [22]. In addition, TACE does
have some contra-indications, both absolute and relative
(Table 1) [22].
Collectively, these ﬁndings indicated that treatment with
TACE may be associated with some beneﬁts in terms of OS,
although the level of beneﬁt varies and considerable AEs may
occur: therefore, a careful selection of patients appears crucial
before the initiation of TACE therapy [3].
In the future, additional trials should be conducted to
investigate some ‘grey areas’ still present in the current
knowledge of TACE, such as the use and type of the
chemotherapeutic agent, as well as the best type of embolizing
medium [3]. Of note, recent evidence supports the use of the
EASL criteria or the mRECIST criteria, rather than the
standard RECIST criteria, in the evaluation of clinical response
after TACE [23]. Gilmore et al. reported a signiﬁcant
association between survival and overall EASL and mRECIST
responses: response was associated with a 44% risk reduction
and mRECIST with a 42% reduction. Conversely, there was no
signiﬁcant association between survival and RECIST 1.1
responses [23]. These data are corroborated by those reported
by Shim et al. [24], who show that the HRs for time to
progression (TTP) and OS in responders were 0.15 (95% CI:
0.10–0.21) and 0.18 (95% CI: 0.13–0.26), respectively, when the
mRECIST deﬁnition of an objective response was used and
0.16 (95% CI: 0.11–0.22) and 0.23 (95% CI: 0.16–0.33),
Figure 1. Locoregional (LR) or medical treatment of patients with
intermediate-stage HCC, either approved or under investigation. Asterisk
denotes only investigational.
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respectively, with the EASL response criteria. In a recent paper,
Kim et al. reached the same conclusions, further supporting
the signiﬁcant association between TACE response and OS
[25].
Selectivity in positioning the catheter may enhance the
efﬁcacy of TACE. Selective TACE indeed comprises the
injection of chemotherapeutic agents into the segmental or
subsegmental branches feeding the tumours [26]. Golﬁeri et al.
[26] compared the effectiveness of selective/superselective
TACE versus standard TACE in determining tumour necrosis,
in a prospective database of 67 consecutive patients (122
nodules, all <5 cm). The mean histological necrosis level was
64.7%; complete tumour necrosis was obtained in 42.6% of the
nodules. When compared with the standard TACE, selective/
superselective TACE was associated with higher mean levels of
necrosis (75.1 versus 52.8%; P = 0.002) and a higher rate of
complete necrosis (53.8 versus 29.8%, P = 0.013). A direct
relationship was reported between the tumour diameter and
the mean tumour necrosis level (59.6% for lesions <2 cm,
68.4% for lesions 2.1–3 cm and 76.2% for lesions >3 cm).
These ﬁndings suggest that selective/superselective TACE may
determine a higher rate of tumour necrosis than the standard
TACE; however, very small nodules (<2 cm) may not respond
as 3–4 cm nodules [26].
drug-eluting beads TACE
DB-TACE uses doxorubicin-loaded beads rather than the
conventional doxorubicin Lipiodol® (Guerbet, Genoa, Italy)
emulsion [3]. It has been suggested that this approach could
result in an overall favourable toxicity proﬁle and antitumor
activity (response rates ranging from 13.3 to 80.7%) [3].
The randomized, controlled PRECISION V trial has
compared DB-TACE with the standard TACE for the treatment
of 212 cirrhotic patients with HCC [27]. At 6 months, the DB-
TACE group showed higher rates of complete response,
objective response and disease control compared with the
cTACE group (Figure 2) [27]. Although the predeﬁned
hypothesis of superiority was not met in the overall population,
patients with Child-Pugh B, Eastern Cooperative Oncology
Group 1, bilobar disease and recurrent disease presented a
signiﬁcant increase in objective response (P = 0.038). In
addition, DB-TACE was associated with a reduction in serious
liver toxicity and a lower rate of doxorubicin-related side-effects
when compared with the standard TACE.
These ﬁndings are overall in line with those reported in
another RCT by Malagari et al. [28], which compared DB-
TACE with doxorubicin (n = 41) and bland embolization
(n = 43). At 6 months, a complete response, assessed with the
EASL criteria, was seen in 11 patients (26.8%) in the DB-TACE
group versus 6 patients (14%) in the bland embolization group,
whereas a partial response was achieved in 19 patients (46.3%)
and 18 (41.9%) patients, respectively. An advantage for DB-
TACE has been also reported in terms of rate of recurrences
and TTP (42.4 ± 9.5 versus 36.2 ± 9.0 weeks; P = 0.008).
The overall favourable efﬁcacy of DB-TACE is further
corroborated by a recent international, long-term (5 years of
follow-up) study [29]. In total, 173 HCC patients not suitable
for curative treatments were enrolled; 41% were classiﬁed as
Child-Pugh B. The OS at 5 years was 22.5%, with higher rates
achieved in Child-Pugh class A compared with Child-Pugh
class B patients (29.4 versus 12.8%). The mean OS was 43.8
months. Multivariate analysis identiﬁed some signiﬁcant and
independent determinants of 5-year survival: these were the
number of lesions, lesion vascularity, initially achieved
complete response and objective response.
In a recent observational study by Burrel et al. [30] (n = 104;
63 patients were BCLC-B), DB-TACE was associated with the
median survival of 48.6 months, and only 10 patients reported
major complications associated with this intervention. This
study conﬁrmed the safety of DB-TACE in patients with HCC
Figure 2. Complete response, objective response and disease control rate
[cumulative number (%) of patients] at 6 months in the PRECISION V
trial (reproduced from Lammer et al. [27], with permission).
Table 1. Absolute and relative contraindications for TACE (reproduced
from Raoul et al. [22], with permission)
Absolute contraindications
• Decompensated cirrhosis (Child-Pugh B ≥8) including:
– Jaundice
– Clinical encephalopathy
– Refractory ascites
– Hepatorenal syndrome
• Extensive tumour with massive replacement of both entire lobes
• Severely reduced portal vein ﬂow (e.g. non-tumoural portal vein
occlusion or hepatofugal blood ﬂow)
• Technical contraindications to hepatic intra-arterial treatment,
e.g. untreatable arteriovenous ﬁstula
• Renal insufﬁciency (creatinine ≥2 mg/dl or creatinine clearance
<30 ml/min)
Relative contraindications
• Tumour size ≥10 cm
• Co-morbidities involving compromised organ function:
– Active cardiovascular disease
– Active lung disease
• Untreated varices at high risk of bleeding
• Bile-duct occlusion or incompetent papilla due to stent or surgery
supplement article Annals of Oncology
ii | Dufour et al. Volume 24 | Supplement 2 | April 2013
and deﬁned the survival gain that can be obtained, providing
key evidence to decide among controversial indications and
TACE [30]. However, these data might not be directly extended
to clinical practice, since they were collected in a single, highly
specialized centre. In addition, included patients had to meet
very stringent selection criteria (preserved liver function,
absence of symptoms, extrahepatic spread or vascular
invasion).
radioembolization
Radioembolization is an investigational technique which
has given some promising results in preliminary experiences
[31–33]. It is deﬁned as the infusion of radioactive substances
(such as Iodine-131-labelled lipiodol or microspheres
containing Yttrium-90) into the hepatic artery [1]. Given the
hypervascularity of HCC, microspheres will be preferentially
delivered to the tumour area and selectively emit high-energy,
low-penetration radiation to the tumour [1]. Salem et al. [31]
have reported the results of a feasibility study which included
291 patients with HCC, who received a total of 526 treatments
with radioembolization. The response rate according to the
EASL criteria was 57%; the overall TTP was 7.9 months.
Survival times were longer in patients with Child-Pugh A (17.2
months) than in those with Child-Pugh B disease (7.7 months;
P = 0.002). Reported toxic effects included fatigue (57%), pain
(23%) and nausea/vomiting (20%); 19% exhibited grade 3/4
bilirubin toxicity. The 30-day mortality rate was 3%.
However, the relevant costs associated with
radioembolization may limit a wide use of this technique [12].
Moreover, the recent EASL Guidelines stressed that, due to the
lack of RCTs comparing radioembolization with
chemoembolization or sorafenib in patients with intermediate-
or advanced-stage HCC, further research is needed to establish
a competitive efﬁcacy role in these populations [1].
sorafenib in the treatment of the
intermediate patient
Sorafenib is currently the only drug approved for the treatment
of patients with advanced HCC (BCLC-C stage); however, the
use of this molecule in the treatment of intermediate patients is
approved in patients with BCLC-B HCC who are unsuitable to
TACE or in whom TACE resulted in unacceptable toxicity
[1,22,34–36]. According to available evidence, sorafenib has a
role in patients who fail or are not eligible to TACE, as recently
suggested by a Panel of Experts [22]. We propose here a
slightly modiﬁed version of the same algorithm (Figure 3).
Bruix et al. [37] carried out a subanalysis of the landmark
SHARP study to compare the efﬁcacy and safety of sorafenib
alone in patients with BCLC-B (sorafenib, n = 54; placebo,
n = 51) versus BCLC-C (sorafenib, n = 245; placebo, n = 252)
stage of HCC. Overall, the beneﬁt determined by sorafenib,
expressed in terms of OS and TTP, was similar in BCLC-B
(median OS: 14.5 months, +39% versus placebo; median TTP:
6.9 months, +113% versus placebo, P = 0.0016) and BCLC-C
(median OS: 9.7 months, +43% versus placebo, P = 0.018;
median TTP: 4.9 months, +69% versus placebo, P = 0.00003)
subgroups and was consistent with that reported in the overall
population [37]. The incidence of grade 3/4 drug-related AEs
was not different in the two subgroups and was similar to that
reported for the overall SHARP study population. The authors
concluded that these ﬁndings conﬁrm a retained efﬁcacy of
sorafenib even in the intermediate-stage HCC [37].
In an observational setting, a subanalysis of the global phase
IV GIDEON study documented an OS of 12.6 months for
BCLC-B patients, as assessed in a cohort of 311 Child-Pugh A
and B patients [38]. In the smaller Italian SOFIA study, the OS
of the 74 BCLC-B patients treated with sorafenib was longer
than that reported in the 222 BCLC-C patients evaluated (20.6
versus 8.4 months; P < 0.0001) [39]. Taken together, these
Figure 3. Proposed algorithm for the treatment of patients with intermediate-stage HCC. Response is deﬁned according to mRECIST criteria.
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preliminary results lend some support to the potential use of
sorafenib monotherapy in patients with BCLC-B stage of HCC.
It is widely accepted that TACE promotes the synthesis of
proangiogenic factors via a hypoxia-driven mechanism [35,40].
Therefore, there may be a rationale for the combination of
sorafenib with TACE, since sorafenib inhibits the action of
proangiogenic factors promoted by TACE [35,40,41].
Preliminary evidence, collected in a phase I trial, shows that
the combination of sorafenib and TACE is not associated with
major AEs and, therefore, could deserve further investigations
[42]. Moreover, given the overall more favourable efﬁcacy/
safety proﬁle of DB-TACE compared with the standard TACE,
the combination of sorafenib with DB-TACE appears
promising. Clinical trials investigating this therapeutic
approach (namely the START, SOCRATES and TACTIS) are
ongoing and will likely provide new evidence on the efﬁcacy
and safety of a combination of TACE and sorafenib in the
treatment of intermediate-stage HCC patients. The results of
the global phase II SPACE trial have been recently published in
an abstract form [43]. In total, 307 patients with BCLC-B stage
of HCC were randomized to sorafenib (n = 154) or placebo
(n = 153) in combination with TACE with doxorubicin-eluting
beads (DEBDOX). Even if this study met its primary end point
from a statistical point of view (P = 0.072 for TTP), the actual
improvement of the median TTP was not clinically relevant
(from 166 to 169 days). The results of other ongoing studies
appear eagerly awaited.
conclusions
Patients with intermediate-stage HCC represent a
heterogeneous population, characterized by varying tumour
burdens, liver function and disease aetiology. Therefore, a ‘one
size ﬁts all’ approach may not be entirely feasible in these
subjects. We believe, in line with current guidelines, that a
multidisciplinary management by specialists with different
expertise may represent the optimal approach for the diagnosis
and treatment of patients classiﬁed as affected from
intermediate-stage HCC.
TACE represents the standard treatment approach in this
population. This therapy is associated with some OS beneﬁts,
although the level of beneﬁt reported varies—according to
patient’s and tumour characteristics as well as the methodology
used. In addition, TACE is not suitable for all patients and can
be associated with the onset of some AEs, although transitory.
Variants of TACE or other locoregional treatments have been
tested, and DB-TACE in particular showed promising results,
but further evidence is necessary to fully support these
approaches. In addition, a very recent paper has documented
the potential beneﬁts of a ‘repeated-TACE’ approach [44], and
research aimed at investigating the factors who can predict a
failure of response with this treatment is active [45].
In our opinion, the potential role of radioembolization, or a
combination of locoregional approaches (see for instance, the
combination of activated liposomal encapsulation of
doxorubicin in combination with radiofrequency ablation,
currently being explored in the HEAT trial NCT00617981), for
the intermediate patients deﬁnitely deserves further
investigations and should be considered from a
multidisciplinary perspective. Lastly, sorafenib, the only
systemic treatment currently approved for the treatment of
HCC, has a role in the treatment of patients with BCLC-B
stage of HCC who are unsuitable to TACE or in whom TACE
resulted in unacceptable toxicity.
Another intriguing arena is represented by the combination
or the sequential use of locoregional approaches and sorafenib.
Moreover, preliminary evidence suggests that sorafenib may be
used in patients who fail or are not eligible to TACE, in a
sequential manner. The potential combination of TACE (either
standard TACE or DB-TACE) and systemic targeted therapy
also represents a promising treatment strategy, currently being
explored in different phase III trials.
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